A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a research study involving 6 weeks of study medication, Ibudilast or a placebo (an
inactive substance) and medical management counseling to reduce or stop drinking. Ibudilast
is not approved by the U.S. FDA for clinical use in the United States, but it is has been
used for many years in Japan for its anti-inflammatory effects. Its use in the treatment of
alcohol dependence is experimental. By reducing inflammation, Ibudilast may help some people
reduce or stop drinking. We have obtained an Investigational New Drug Application (IND)
approval for this study from the FDA. Ibudilast has been used clinically for 20 years in Asia
for treating bronchial asthma and, more recently, for post-stroke dizziness and ocular
allergies and has been shown to be safe and well tolerated.